228.
Яновский, А
. Как финансировать проекты по коммерциализации
технологий [Текст]: руководство VIII из серии
методических материалов
«Практические руководства для центров коммерциализации технологий»,
подготовлена под рук. П. Линдхольма/ А. Яновский. – М., 2006. – 47 с.
229.
Abi Hussein, H
. Global vision of druggability issues: applications and
perspectives [Текст] / H. Abi Hussein, C. Geneix, M. Petitjean [et al.] //Drug
Discovery Today. – 2017. – V. 22, №2. – р. 404–415.
230. ACDLab [Электронный ресурс]. – Режим доступа: www.acdlabs.com.
231. ADMET Prediction Service [Электронный ресурс]. – Режим доступа:
qsar.chem.msu.ru/admet.
232. American nuclear guinea pigs: three decades of radiation experiments
on U. S. citizens [Электронный ресурс] // Congressional hearings from the
University of Nevada. – 2010. – Режим доступа: contentdm.library.unr.edu/
cdm/singleitem/collection/conghear/id/102#metajump.
233. An, J. Сomprehensive identification of "druggable" protein ligand binding
sites [Текст] / J. An, M. Totrov, R. Abagyan [et al.]// Genome Information. –
2004. – V. 15, №2. – р. 31–41.
234.
Alqahtani, S
. In silico ADME–Tox modeling:
progress and prospects
[Текст] / S. Alqahtani // Expert Opinion on Drug Metabolism and Toxicology.
–2017. – V. 13, №11. – р. 1147–1158.
235.
Andrade, E.L
. Non-clinical studies required for new drug development –
Part I: early in silico and in vitro studies, new target discovery and validation, proof
of principles and robustness of animal studies [Текст] / E.L. Andrade, A.F. Bento, J.
Cavalli [et al.] // Brazilian Journal of Medical and Biological Research. – 2016. – V.
11, №49. – р. 5644.
236. Application of Hazard Analysis and Critical Control Point (HACCP)
methodology to pharmaceuticals [Текст] / WHO Technical Report Seriesю –
2003. – №908, Annex 7. – p. 99–112.
237.
Arnott, J.A
. The influence of lipophilicity in drug discovery and design
[Текст] / J.A. Arnott, S.L. Planey // Expert Opin Drug Discov. – 2012. – V. 10,
№7. – p. 863–875.
238.
Arkin, M.R
. Small-molecule inhibitors of protein-protein interactions:
progressing toward the reality [Текст] / M.R. Arkin, Y. Tang, J.A. Wells //
Chemistry and biology. – 2014. – V. 21, №9. – р. 1102–1114.
239.
Austin, C.P.
NIH Molecular Libraries Initiative [Текст] / Austin C.P.,
Brady L.S., Insel T.R. [et al.]// Science. – 2004. – V. 306, №5699. – р. 1138–1139.
240.
Bakal, C.W.
Mentally retarded hepatitis-B surface antigen carriers in
NYC public school classes: a public health dilemma [Электронный ресурс]/
C.W. Bakal, L.F. Novick, J.S. Marr // NCBI. – 1980. – Режим доступа: www.
ncbi.nlm.nih.gov/pmc/articles/PMC1619463/.
241.
Bates, D.O
. Pharmacology of modulators of alternative splicing [Текст]
/ D.O. Bates, J.C. Morris, S. Oltean [et al.] // Pharmacological Reviews. – 2017.
– V. 69, №1. – р. 63–79.
242.
Baker, D
. Protein structure prediction and structural genomics [Текст] /
D. Baker, A. Sali // Science. – 2001. – V. 294, №5540. – р. 93–96.
243.
Bender, A
. How similar are those molecules after all? Use two descriptors
and you will have three different answers [Текст] / A. Bender // Expert Opinion
on Drug Discovery. – 2010. – V. 5, №12. – р. 1141–1151.
Список литературы
373
244.
Bhal, S.K
. The Rule of Five revisited: applying log D in place of log
P in drug–likeness filters / S. K. Bhal, K. Kassam, I. G. Peirson // Molecular
Pharmaceutics. – 2007. – V. 4, №4. – р. 556–560.
245.
Bharate, S.S.
Interactions and incompatibilities of pharmaceutical
excipients with active pharmaceutical ingredients:
a comprehensive review
[Текст] / S. S. Bharate, S. B. Bharate, A. N. Bajajc // Journal of Excipients and
Food Chemicals. – 2010. – №3. – p. 3–26.
246. Biovia [Электронный ресурс]. – Режим доступа: www.3dsbiovia.com
247.
Boran, A.D
. Systems approaches to polypharmacology and drug
discovery [Текст] / A. D. Boran, R. Iyengar // Current Opinion in Drug Discovery
and Development. – 2010. – V. 13, №3. – р. 297–309.
248.
Borodina, Y.
A new statistical approach to predicting aromatic
hydroxylation sites.comparison with model–based approaches [Текст] /
Y. Borodina, A.rudik, D. Filimonov [et al.] // Journal of Chemical Information
and Computer Sciences. – 2004. – V. 6, №44. – р. 1998–2009.
249.
Bosch, F
. The contributions of Paul Ehrlich to pharmacology: a tribute
on the occasion of the centenary of his Nobel Prize [Текст] / F. Bosch, L. Rosich
//Pharmacology. – 2008. – V. 82, №3. – р. 171–179.
250.
Brindle, A
. Risk Analysis and Mitigation Matrix (RAMM) –
A Risk
Tool for Quality Management [Текст] / A. Brindle, S. Davy, D. Tiffany, [et al.] //
Pharmaceutical Engineering. – 2012. – V. 32, №1. – p. 26–33.
251. Bristol–Myers Squibb. REYATAZ® (atazanavir sulfate) Capsules.
Prescription Drug Information In: Bristol–Myers Squibb Company [Текст] /
Princeton, NJ 08543 USA; 2007.
252. ChemNavigator [Электронный ресурс]. – Режим доступа: www.
chemnavigator.com.
253. ChEMBL [Электронный ресурс]. – Режим доступа: www.ebi.ac.uk/
chembl.
254. Chemical Biology Platform Screening Unit [Электронный ресурс]. –
Режим доступа: www.leibniz-fmp.de/core-facilities/screening–unit/screening–
unit/intro.html.
255. ChemProt [Электронный ресурс]. – Режим доступа: potentia. cbs. dtu.
dk/ChemProt/.
256.
Chen, H
. Cheminformatics in Drug Discovery, an Industrial Perspective
[Текст] / H. Chen, T. Kogej, O. Engkvist //Molecular Informatics. – 2018. – V. 37,
№9–10. – Режим доступа: bigchem.eu/sites/default/files/Hongming_Chen.pdf.
257.
Chen, Y.C
. Beware of docking! [Текст] / Y. C. Chen // Trends in
Pharmacological Sciences. – 2015. – V. 36, №2. – p. 78–95.
258.
Chung, S.C
. Technology Transfer and International Cooperation /
S.C. Chung, L.M. Branscomb //Branscomb and Choi (Ed). – Korea at the
Turning Point, Westport: Praeger. – 1996.
259.
Chung, S
. Innovation, Competitiveness and Growth: Korean Experiences.
– Research Fellow Emeritus, Science and Technology Policy Institute (STEPI). –
STEPI, Seoul. – 2009.
260. Clarivate Analytics Integrity [Электронный ресурс]. – Режим доступа:
integrity. clarivate.com.
261. Clinical trial designs [Электронный ресурс]. – EUPATI, 2015. – Режим
доступа: www.eupati.eu/clinical-development-and-trials/clinical-trial-designs.
374
Достарыңызбен бөлісу: